Literature DB >> 2370933

Successful treatment of hemodialysis-related porphyria cutanea tarda with deferoxamine.

F Stockenhuber1, R Kurz, G Grimm, G Moser, P Balcke.   

Abstract

End-stage renal failure and long-term hemodialysis treatment promote the development of genetically conditioned porphyria cutanea tarda (PCT). The clinical manifestation is triggered off by unknown factors coexisting with renal insufficiency and hemodialysis. Iron overload is often associated with the disease and is thought to play a key role in its pathogenesis. Iron removal by deferoxamine infusions is regarded as the treatment of choice for patients who cannot undergo repeated phlebotomy procedures and has been successfully used in patients with normal renal function. We report a case of hemodialysis-related PCT and iron overload in whom repeated venesections were contraindicated on account of severe anemia and treatment with deferoxamine led to a striking improvement of symptoms.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2370933     DOI: 10.1159/000185983

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  2 in total

1.  Acute renal failure following deferoxamine overdose.

Authors:  Salvatore Li Volti; Carmela Maccarone; Giovanni Li Volti; Maria A Romeo
Journal:  Pediatr Nephrol       Date:  2003-08-14       Impact factor: 3.714

2.  [High-dose vitamin therapy as prophylaxis against porphyria cutanea uremica].

Authors:  F Wimmershoff; K Gardlo; K Bolsen; T Ruzicka; C Fritsch
Journal:  Hautarzt       Date:  2006-03       Impact factor: 0.751

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.